Inpatient Influenza Prevention and Treatment

Inpatient Influenza Prevention and Treatment

CDC Guidance

The Centers for Disease Control and Prevention (CDC) has provided guidance for the treatment of seasonal influenza for the 2022-2023 influenza season. For full details, refer to CDC website


Influenza vaccine is recommended for all persons aged ≥6 months who do not have contraindications


Treatment aimed for high-risk patients, including immunosuppressed (cancer, HIV, AIDS, transplant) patients, pregnant patients, adults ≥65 years old, and patients with asthma, chronic heart disease, or diabetes

Treatment options can lessen symptoms (including pneumonia) by 1-2 days and decrease length of stay when started within 2 days of symptoms

More Information

  1. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021;70(5):1-28.
  2. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349-61. DOI: 10.3851/IMP2680.
  3. Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012 Dec;32(12):1061-9.
  4. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58:309–318.
  5. Food and Drug Administration. Emergency use authorization of peramivir IV. Fact sheet for health care providers. November 19, 2009. Accessed August 24, 2021.